76 related articles for article (PubMed ID: 23860928)
1. Increased expression of mitotic arrest deficient-like 1 (MAD1L1) is associated with poor prognosis and insensitive to Taxol treatment in breast cancer.
Sun Q; Zhang X; Liu T; Liu X; Geng J; He X; Liu Y; Pang D
Breast Cancer Res Treat; 2013 Jul; 140(2):323-30. PubMed ID: 23860928
[TBL] [Abstract][Full Text] [Related]
2. Mitotic arrest deficient-like 1 is correlated with poor prognosis in small-cell lung cancer after surgical resection.
Li D; Meng Q; Zhang H; Feng T; Liu M; Cai L
Tumour Biol; 2016 Apr; 37(4):4393-8. PubMed ID: 26499943
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability.
Yuan B; Xu Y; Woo JH; Wang Y; Bae YK; Yoon DS; Wersto RP; Tully E; Wilsbach K; Gabrielson E
Clin Cancer Res; 2006 Jan; 12(2):405-10. PubMed ID: 16428479
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the mitotic check point gene, MAD1L1, in human cancers.
Tsukasaki K; Miller CW; Greenspun E; Eshaghian S; Kawabata H; Fujimoto T; Tomonaga M; Sawyers C; Said JW; Koeffler HP
Oncogene; 2001 May; 20(25):3301-5. PubMed ID: 11423979
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
6. Low cdc27 and high securin expression predict short survival for breast cancer patients.
Talvinen K; Karra H; Pitkänen R; Ahonen I; Nykänen M; Lintunen M; Söderström M; Kuopio T; Kronqvist P
APMIS; 2013 Oct; 121(10):945-53. PubMed ID: 23755904
[TBL] [Abstract][Full Text] [Related]
7. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
8. Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.
Sun S; Liang X; Zhang X; Liu T; Shi Q; Song Y; Jiang Y; Wu H; Jiang Y; Lu X; Pang D
Br J Cancer; 2015 Apr; 112(8):1332-9. PubMed ID: 25867275
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
10. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
[TBL] [Abstract][Full Text] [Related]
11. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
12. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of minichromosome maintenance 2 predicts poor prognosis in patients with gastric cancer.
Yang C; Wen Y; Li H; Zhang D; Zhang N; Shi X; Jiang B; Ma X; Yang P; Tang H; Peng Z; Yang Y
Oncol Rep; 2012 Jan; 27(1):135-42. PubMed ID: 21947329
[TBL] [Abstract][Full Text] [Related]
14. CHFR-associated early G2/M checkpoint defects in breast cancer cells.
Erson AE; Petty EM
Mol Carcinog; 2004 Jan; 39(1):26-33. PubMed ID: 14694445
[TBL] [Abstract][Full Text] [Related]
15. Expression of 14-3-3γ in patients with breast cancer: correlation with clinicopathological features and prognosis.
Song Y; Yang Z; Ke Z; Yao Y; Hu X; Sun Y; Li H; Yin J; Zeng C
Cancer Epidemiol; 2012 Dec; 36(6):533-6. PubMed ID: 22658894
[TBL] [Abstract][Full Text] [Related]
16. Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis.
Rakha EA; Pinder SE; Paish EC; Robertson JF; Ellis IO
J Pathol; 2004 Jul; 203(3):754-61. PubMed ID: 15221934
[TBL] [Abstract][Full Text] [Related]
17. Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer.
Horak CE; Pusztai L; Xing G; Trifan OC; Saura C; Tseng LM; Chan S; Welcher R; Liu D
Clin Cancer Res; 2013 Mar; 19(6):1587-95. PubMed ID: 23340299
[TBL] [Abstract][Full Text] [Related]
18. Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells.
Inaba S; Li C; Shi YE; Song DQ; Jiang JD; Liu J
Breast Cancer Res Treat; 2005 Nov; 94(1):25-35. PubMed ID: 16142440
[TBL] [Abstract][Full Text] [Related]
19. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin.
Pohl G; Rudas M; Dietze O; Lax S; Markis E; Pirker R; Zielinski CC; Hausmaninger H; Kubista E; Samonigg H; Jakesz R; Filipits M
J Clin Oncol; 2003 Oct; 21(19):3594-600. PubMed ID: 14512390
[TBL] [Abstract][Full Text] [Related]
20. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.
Wu K; Quan Z; Weng Z; Li F; Zhang Y; Yao X; Chen Y; Budman D; Goldberg ID; Shi YE
Breast Cancer Res Treat; 2007 Mar; 101(3):259-67. PubMed ID: 16821081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
